Title: Novel reversible monoamine oxidase A inhibitors: highly potent and selective 3-(1H-pyrrol-3-yl)-2-oxazolidinones.
Journal: Journal of medicinal chemistry20111208
Title: Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia.
Journal: Journal of neural transmission (Vienna, Austria : 1996)20111201
Title: Up-regulation of the isoenzymes MAO-A and MAO-B in the human basal ganglia and pons in Huntington's disease revealed by quantitative enzyme radioautography.
Journal: Brain research20110125
Title: Combined treatment with MAO-A inhibitor and MAO-B inhibitor increases extracellular noradrenaline levels more than MAO-A inhibitor alone through increases in beta-phenylethylamine.
Journal: European journal of pharmacology20100710
Title: Molecular dynamics, flexible docking, virtual screening, ADMET predictions, and molecular interaction field studies to design novel potential MAO-B inhibitors.
Journal: Journal of biomolecular structure & dynamics20080201
Title: Autoradiographical distribution of imidazoline binding sites in monoamine oxidase A deficient mice.
Journal: Journal of neurochemistry20060301
Title: Effect of co-administration of subchronic lithium pretreatment and acute MAO inhibitors on extracellular monoamine levels and the expression of contextual conditioned fear in rats.
Journal: European journal of pharmacology20060227
Title: Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds.
Journal: Bioorganic & medicinal chemistry letters20051015
Title: Characterisation of imidazoline I2 binding sites in pig brain.
Journal: European journal of pharmacology20050905
Title: High-affinity binding of beta-carbolines to imidazoline I2B receptors and MAO-A in rat tissues: norharman blocks the effect of morphine withdrawal on DOPA/noradrenaline synthesis in the brain.
Journal: European journal of pharmacology20050822
Title: Monoamine oxidase B inhibitors for early Parkinson's disease.
Journal: The Cochrane database of systematic reviews20050720
Title: Effects of depression, cigarette smoking, and age on monoamine oxidase B in amygdaloid nuclei.
Journal: Brain research20050510
Title: Locomotor effects of imidazoline I2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway.
Journal: British journal of pharmacology20041201
Title: Clinical trials of neuroprotection for Parkinson's disease.
Journal: Neurology20041012
Title: SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
Journal: The Journal of pharmacology and experimental therapeutics20040901
Title: Differential substrate specificity of monoamine oxidase in the rat heart and renal cortex.
Journal: Life sciences20030711
Title: Serotonin transporter and MAO-B levels in monoamine nuclei of the human brainstem are normal in major depression.
Journal: Journal of psychiatric research20030101
Title: Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation.
Journal: Addiction (Abingdon, England)20021001
Title: Lifestyle drug market booming.
Journal: Nature medicine20020901
Title: Inhibition of monoamine oxidase modulates the behaviour of semicarbazide-sensitive amine oxidase (SSAO).
Journal: Journal of neural transmission (Vienna, Austria : 1996)20020301
Title: Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism.
Journal: European journal of pharmacology20010518
Title: Antioxidant activity of the monoamine oxidase B inhibitor lazabemide.
Journal: Biochemical pharmacology20000901
Title: Safety study of lazabemide (Ro19-6327), a new MAO-B inhibitor, on cardiac arrhythmias and blood pressure of patients with Parkinson's disease.
Journal: Clinical neuropharmacology19990101
Title: Increased density of catalytic sites and expression of brain monoamine oxidase A in humans with hepatic encephalopathy.
Journal: Journal of neurochemistry19970301
Title: Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group.
Journal: Annals of neurology19960701
Title: Molecular neuroanatomy of human monoamine oxidases A and B revealed by quantitative enzyme radioautography and in situ hybridization histochemistry.
Journal: Neuroscience19960201
Title: Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography.
Journal: Neuroscience19940901
Title: Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: preclinical and clinical findings.
Journal: Journal of neural transmission. Supplementum19940101
Title: Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by Ro 19 6327.
Journal: Neurology19931001
Title: Ro 19-6327, a reversible and highly selective monoamine, oxidase B inhibitor: a novel tool to explore the MAO-B function in humans.
Journal: Advances in neurology19900101
Title: Saura J, et al. Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J Neurosci. 1992 May;12(5):1977-99.
Title: Bondiolotti GP, et al. In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: a comparison with L-deprenyl. Biochem Pharmacol. 1995 Jun 29;50(1):97-102.
Title: Guimaraes J, et al. The activity of MAO A and B in rat renal cells and tubules. Life Sci. 1998;62(8):727-37.
Title: Suzuki T, et al. MAO inhibitors, clorgyline and lazabemide, prevent hydroxyl radical generation caused by brain ischemia/reperfusion in mice. Pharmacology. 1995 Jun;50(6):357-62.
